Aviance Capital Partners LLC cut its holdings in shares of Celgene Co. (NASDAQ:CELG) by 35.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,690 shares of the biopharmaceutical company’s stock after selling 4,704 shares during the period. Aviance Capital Partners LLC’s holdings in Celgene were worth $803,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Archford Capital Strategies LLC increased its stake in shares of Celgene by 277.8% in the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 200 shares in the last quarter. Liberty Wealth Management LLC increased its stake in Celgene by 212.8% during the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 200 shares in the last quarter. Weaver Consulting Group bought a new stake in Celgene during the 1st quarter valued at about $29,000. Alera Investment Advisors LLC increased its stake in Celgene by 109.9% during the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 167 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. bought a new stake in Celgene during the 1st quarter valued at about $31,000. 72.51% of the stock is owned by institutional investors.
A number of analysts have recently commented on CELG shares. Cowen reiterated a “hold” rating and issued a $102.00 price target on shares of Celgene in a research note on Tuesday, July 30th. BidaskClub lowered shares of Celgene from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Mizuho lowered shares of Celgene from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $103.00 to $100.00 in a research note on Monday, August 19th. ValuEngine lowered shares of Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price objective on the stock in a report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $94.60.
Shares of Celgene stock traded up $0.22 on Friday, hitting $98.85. 67,934 shares of the company traded hands, compared to its average volume of 3,024,607. The stock has a market capitalization of $69.21 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 0.46 and a beta of 1.41. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.32 and a current ratio of 3.44. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $99.06. The business has a 50-day simple moving average of $94.93 and a 200 day simple moving average of $93.38.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, topping the consensus estimate of $2.44 by $0.17. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The company had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.22 billion. During the same quarter in the previous year, the business posted $2.16 earnings per share. Celgene’s quarterly revenue was up 15.4% on a year-over-year basis. Research analysts expect that Celgene Co. will post 9.96 earnings per share for the current year.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Recommended Story: How is a price target determined?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.